CA2734535C - Lung cancer biomarkers and uses thereof - Google Patents

Lung cancer biomarkers and uses thereof Download PDF

Info

Publication number
CA2734535C
CA2734535C CA2734535A CA2734535A CA2734535C CA 2734535 C CA2734535 C CA 2734535C CA 2734535 A CA2734535 A CA 2734535A CA 2734535 A CA2734535 A CA 2734535A CA 2734535 C CA2734535 C CA 2734535C
Authority
CA
Canada
Prior art keywords
biomarkers
biomarker
individual
lung cancer
aptamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2734535A
Other languages
English (en)
French (fr)
Other versions
CA2734535A1 (en
Inventor
Larry Gold
Marty Stanton
Edward N. Brody
Rachel M. Ostroff
Dominic Zichi
Alex A. E. Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Operating Co Inc
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Priority to CA3011730A priority Critical patent/CA3011730C/en
Publication of CA2734535A1 publication Critical patent/CA2734535A1/en
Application granted granted Critical
Publication of CA2734535C publication Critical patent/CA2734535C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Mathematical Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Databases & Information Systems (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Analysis (AREA)
  • Pure & Applied Mathematics (AREA)
  • Computational Mathematics (AREA)
  • Software Systems (AREA)
  • Algebra (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2734535A 2008-09-09 2009-09-09 Lung cancer biomarkers and uses thereof Active CA2734535C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3011730A CA3011730C (en) 2008-09-09 2009-09-09 Lung cancer biomarkers and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9559308P 2008-09-09 2008-09-09
US61/095,593 2008-09-09
US15283709P 2009-02-16 2009-02-16
US61/152,837 2009-02-16
PCT/US2009/056399 WO2010030697A1 (en) 2008-09-09 2009-09-09 Lung cancer biomarkers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3011730A Division CA3011730C (en) 2008-09-09 2009-09-09 Lung cancer biomarkers and uses thereof

Publications (2)

Publication Number Publication Date
CA2734535A1 CA2734535A1 (en) 2010-03-18
CA2734535C true CA2734535C (en) 2018-08-28

Family

ID=42005456

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2734535A Active CA2734535C (en) 2008-09-09 2009-09-09 Lung cancer biomarkers and uses thereof
CA3011730A Active CA3011730C (en) 2008-09-09 2009-09-09 Lung cancer biomarkers and uses thereof
CA3152591A Active CA3152591C (en) 2008-09-09 2009-09-09 Lung cancer biomarkers and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3011730A Active CA3011730C (en) 2008-09-09 2009-09-09 Lung cancer biomarkers and uses thereof
CA3152591A Active CA3152591C (en) 2008-09-09 2009-09-09 Lung cancer biomarkers and uses thereof

Country Status (14)

Country Link
EP (1) EP2340506B1 (enExample)
JP (1) JP5701212B2 (enExample)
KR (1) KR101658347B1 (enExample)
CN (2) CN104198709A (enExample)
AU (2) AU2009291811B2 (enExample)
CA (3) CA2734535C (enExample)
DK (1) DK2340506T3 (enExample)
ES (1) ES2559758T3 (enExample)
GB (1) GB2478441B (enExample)
HK (1) HK1204062A1 (enExample)
HR (1) HRP20160127T1 (enExample)
MX (1) MX2011002322A (enExample)
SI (1) SI2340506T1 (enExample)
WO (1) WO2010030697A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CA3024643C (en) 2009-03-12 2021-08-03 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof including gender-based disease identification, assessment, prevention and therapy
MX2012014268A (es) * 2010-07-09 2013-02-12 Somalogic Inc Biomarcadores de cancer de pulmon y usos de los mismos.
EP2603622A4 (en) 2010-08-13 2015-04-22 Somalogic Inc BIOMARKERS FOR PANCREATIC CANCER AND USES THEREOF
DK2694964T3 (da) * 2011-04-07 2019-10-07 Scripps Research Inst High-throughput-screening for forbindelser, der modulerer niveauer af cellulære makromolekyler
CA2834383A1 (en) * 2011-04-29 2012-11-01 Cancer Prevention And Cure, Ltd. Methods of identification and diagnosis of lung diseases using classification systems and kits thereof
IN2014CN01787A (enExample) * 2011-10-24 2015-05-29 Somalogic Inc
AU2012358246B2 (en) * 2011-12-21 2018-01-25 Integrated Diagnostics, Inc. Methods for diagnosis of lung cancer
US11913957B2 (en) 2011-12-21 2024-02-27 Biodesix, Inc. Compositions, methods and kits for diagnosis of lung cancer
US9304137B2 (en) 2011-12-21 2016-04-05 Integrated Diagnostics, Inc. Compositions, methods and kits for diagnosis of lung cancer
JP6215845B2 (ja) * 2012-02-17 2017-10-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 急性肺損傷（ａｌｉ）／急性呼吸窮迫症候群（ａｒｄｓ）アセスメント及びモニタリング
US9103837B2 (en) 2012-11-07 2015-08-11 Somalogic, Inc. Chronic obstructive pulmonary disease (COPD) biomarkers and uses thereof
AU2014347669C1 (en) * 2013-11-07 2021-03-11 Medial Research Ltd. Methods and systems of evaluating a risk of lung cancer
WO2017043679A1 (en) * 2015-09-11 2017-03-16 Aptamer Sciences Inc. Protein biomarker panel for detecting non-small cell lung cancer and method for diagnosing a non-small cell lung cancer by the use thereof
FR3050269B1 (fr) 2016-04-15 2018-05-11 Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris (Espci) Procede de selection et de recuperation de produits et systeme associe
CN105823665A (zh) * 2016-05-13 2016-08-03 北京九州柏林生物科技有限公司 生物组织样本制备套液
CN109715830A (zh) 2016-06-21 2019-05-03 威斯塔解剖学和生物学研究所 用于使用基因表达谱诊断肺癌的组合物和方法
JP6280997B1 (ja) * 2016-10-31 2018-02-14 株式会社Preferred Networks 疾患の罹患判定装置、疾患の罹患判定方法、疾患の特徴抽出装置及び疾患の特徴抽出方法
EP3607089A4 (en) 2017-04-04 2020-12-30 Lung Cancer Proteomics, LLC PLASMA-BASED PROTEIN PROFILING FOR EARLY PROGNOSIS OF LUNG CANCER
AU2018324195B2 (en) 2017-09-01 2024-12-12 Venn Biosciences Corporation Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
CA3085464A1 (en) 2017-12-19 2019-06-27 The Wistar Institute Of Anatomy And Biology Compositions and methods for diagnosing lung cancers using gene expression profiles
EP3810563A4 (en) * 2018-06-22 2022-03-23 Somalogic, Inc. IMPROVED PROTEOMIC MULTIPLEX TESTS
US20220397575A1 (en) * 2019-06-21 2022-12-15 National University Of Singapore Methods for determining the likelihood of lung cancer
CN110579611B (zh) * 2019-09-18 2023-01-31 郑州大学 一种用于肺癌早期筛查和诊断的联合检测血清标志物、试剂盒及检测方法
CN111047609B (zh) * 2020-03-13 2020-07-24 北京深睿博联科技有限责任公司 肺炎病灶分割方法和装置
CN113960235B (zh) * 2020-10-10 2023-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 生物标志物在制备肺癌检测试剂中的用途和方法
CN112557514B (zh) * 2020-12-22 2021-09-21 中国海洋大学 手持式海底沉积物样品剖面声学全自动测量装置
TW202242146A (zh) * 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
WO2025137139A1 (en) * 2023-12-18 2025-06-26 Caris Mpi, Inc. Dynamic tissue typing

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596503B1 (en) * 2000-08-18 2003-07-22 East Carolina University Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
US6939670B2 (en) * 2001-03-12 2005-09-06 Monogen, Inc. Cell-based detection and differentiation of lung cancer
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
AU2003294377A1 (en) * 2002-12-18 2004-07-29 Ciphergen Biosystems, Inc. Serum biomarkers in lung cancer
CN1225477C (zh) * 2003-03-28 2005-11-02 上海市疾病预防控制中心 肺癌早期血清特异蛋白及其应用
CN1455257A (zh) * 2003-05-23 2003-11-12 北京师范大学 一种利用表面修饰蛋白芯片进行肺癌诊断方法
TW200600785A (en) * 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
JP2005304497A (ja) * 2004-03-25 2005-11-04 Joji Inasawa 特定の癌関連遺伝子を用いる癌の検出方法及び癌の抑制方法
ES2367311T3 (es) * 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
WO2005103281A2 (en) * 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
WO2006022895A2 (en) * 2004-08-02 2006-03-02 Children's Medical Center Corporation Platelet biomarkers for cancer
CN1873417A (zh) * 2005-06-02 2006-12-06 中国医学科学院肿瘤医院肿瘤研究所 一种用于诊断肺癌的蛋白质芯片
EP3153860A3 (en) * 2005-12-22 2017-06-14 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
AU2007313551A1 (en) * 2006-10-17 2008-04-24 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
US20110119776A1 (en) * 2007-02-05 2011-05-19 Wong Kwok-Kin Methods of diagnosing and prognosing lung cancer
KR100846354B1 (ko) * 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
AU2008254786A1 (en) * 2007-05-18 2008-11-27 University Of Southern California Germline polymorphisms in the angiogenic pathway predict tumor recurrence in cancer therapy
US7888051B2 (en) * 2007-09-11 2011-02-15 Cancer Prevention And Cure, Ltd. Method of identifying biomarkers in human serum indicative of pathologies of human lung tissues
WO2010003772A1 (en) * 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Method for predicting adverse response to erythropoietin in breast cancer treatment
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
AU2011215789A1 (en) * 2010-02-10 2012-08-30 The Regents Of The University Of California Salivary biomarkers for lung cancer detection

Also Published As

Publication number Publication date
DK2340506T3 (en) 2016-02-08
WO2010030697A1 (en) 2010-03-18
EP2340506B1 (en) 2015-11-11
AU2015249113A1 (en) 2015-11-12
EP2340506A1 (en) 2011-07-06
CA3152591C (en) 2023-08-29
HK1204062A1 (en) 2015-11-06
KR20110063753A (ko) 2011-06-14
EP2340506A4 (en) 2012-02-15
MX2011002322A (es) 2011-05-10
CA2734535A1 (en) 2010-03-18
GB2478441A (en) 2011-09-07
HRP20160127T1 (hr) 2016-03-11
CA3011730A1 (en) 2010-03-18
JP2012502281A (ja) 2012-01-26
CN102209968A (zh) 2011-10-05
CN104198709A (zh) 2014-12-10
SI2340506T1 (sl) 2016-02-29
KR101658347B1 (ko) 2016-09-21
AU2009291811B2 (en) 2015-10-29
GB201106053D0 (en) 2011-05-25
CA3011730C (en) 2022-05-17
CA3152591A1 (en) 2010-03-18
CN102209968B (zh) 2016-05-04
JP5701212B2 (ja) 2015-04-15
HK1153834A1 (en) 2012-04-05
ES2559758T3 (es) 2016-02-15
AU2009291811A1 (en) 2010-03-18
AU2015249113B2 (en) 2017-09-07
GB2478441B (en) 2013-03-27

Similar Documents

Publication Publication Date Title
EP2340506B1 (en) Lung cancer biomarkers and uses thereof
US11221340B2 (en) Lung cancer biomarkers and uses thereof
US10359425B2 (en) Lung cancer biomarkers and uses thereof
AU2011289284B2 (en) Pancreatic cancer biomarkers and uses thereof
EP2771692B1 (en) Lung cancer biomarkers and uses thereof
US20120143805A1 (en) Cancer Biomarkers and Uses Thereof
WO2011043840A1 (en) Cancer biomarkers and uses thereof
US20120165217A1 (en) Cancer Biomarkers and Uses Thereof
WO2010042525A1 (en) Ovarian cancer biomarkers and uses thereof
US20220065872A1 (en) Lung Cancer Biomarkers and Uses Thereof
HK1153834B (en) Lung cancer biomarkers and uses thereof
HK1196429A (en) Lung cancer biomarkers and uses thereof
HK1196429B (en) Lung cancer biomarkers and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140821

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240830

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240830

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240830

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250909